question · intermediate · partly written
If CAR T cells are the patient own cells, why are there antibodies to them, and why do those antibodies not wipe them out?
FDA reviewers reported antibodies against the mouse-derived CAR binder in most tisagenlecleucel patients before infusion, with no apparent effect on expansion or response; no opened source explains why.
The puzzle
The cells are the patient own, yet antibodies exist against the receptor, and they did not stop expansion or response in the FDA review. Candidate reasons are untested here. 1
Reported, not yet replicated
Observation
The FDA 2017 review of tisagenlecleucel reported antibodies against the CAR before infusion in 86% of patients and induced in 37%, with no apparent effect on expansion or response. The cells carry the patient own HLA, so the foreign part is the mouse-derived antibody fragment of the receptor. 1
Reported, not yet replicated
Hypotheses
Lymphodepletion blunts the response
The chemotherapy before infusion lowers the lymphocytes that would respond to the binder. 2
Predicts. Less effect where lymphodepletion is lighter.
Would falsify. Equal antibody effect regardless of lymphodepletion intensity.
Our inference
The assay measures binding, not neutralisation
Antibodies that bind the binder in a lab assay may not block it on cells. 1
Predicts. Neutralising titres, not binding titres, would predict loss of expansion.
Would falsify. Neutralising titres also fail to predict expansion.
Our inference
What is missing
Neutralisation data
No opened source compares binding antibodies with neutralising antibodies against the CAR. 1
Our inference
What is known
Antibodies against the CAR binder are common before and after infusion, and the FDA review found no apparent effect on expansion or response. 1
Reported, not yet replicated
What is not
Why they have no effect is untested in any source opened here; the two figures in the FDA review and in the 2025 label differ and were not reconciled (see the CAR T drug records). 1
Our inference
What would settle it
Neutralisation assays and expansion data stratified by antibody titre, in a source that gives the numbers. 1
Our inference
Still open here
- Which regimen, tissue-access or assay explanation holds?
Not yet written: Who works on it.
Sources
- FDA Summary Basis for Regulatory Action: Kymriah (tisagenlecleucel). FDA (2017). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Turtle, C. J., et al.. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Science Translational Medicine (2016). paper; opened 2026-11-17 all records citing this
History of this record (1)
This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Kind
- big-open
- Register
- open-question
- Triage
- needs-research
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/questions/why-anti-car-antibodies-do-not-clear-the-cells.json